Skip to content CAR-T cell therapy is a cutting-edge personalized immunotherapy that is being actively applied to the treatment of gastric cancer. BIOOCUS has developed CAR-T products targeting gastric cancer-specific antigens such as Claudin18.2 and HER2, showing significant efficacy in patients who have failed multiple prior treatments—for example, CT041 achieved an ORR of 57.1%, DCR of 75%, and a 6-month overall survival rate of 81.2%. Leveraging an international GMP-grade platform, a multidisciplinary expert team, and extensive global clinical experience, BIOOCUS provides a safe, effective, and comprehensive CAR-T therapy solution for gastric cancer patients.
Highly Specific Targeting: By directing CAR-T cells against CLDN18.2 or HER2, gastric cancer cells can be precisely identified and eliminated, minimizing off-tumor effects.
Overcoming Multiline Treatment Resistance: In CT041 trials, the gastric cancer cohort achieved an objective response rate (ORR) of 57.1%, disease control rate (DCR) of 75.0%, and a 6-month overall survival (OS) of 81.2% in patients who had failed multiple prior lines of therapy.
Durable Responses: CLDN18.2-CAR-T treatment yielded a 6-month duration of response rate of 44.8%, suggesting potential for long-term clinical benefit.
Personalized Therapy: Using the patient’s own T cells reduces the risk of rejection and enhances safety and efficacy.
Peripheral Blood T-Cell Collection
T cells are isolated from the patient’s peripheral blood via leukapheresis.
Genetic Engineering
In a GMP-compliant laboratory, T cells are transduced to express a CAR targeting CLDN18.2 or HER2, then expanded ex vivo.
Lymphodepleting Conditioning
A preparative regimen of cyclophosphamide and fludarabine is administered to deplete endogenous lymphocytes and create a favorable niche for CAR-T cell expansion.
CAR-T Cell Infusion
The engineered CAR-T cells are infused back into the patient intravenously.
Monitoring and Management
After infusion, patients are closely monitored for cytokine release syndrome (CRS) and neurotoxicity, with timely interventions as needed.
Optimized by Seraphinite Accelerator
